|
1
|
GBD 2017 Oesophageal Cancer Collaborators,
. The global, regional, and national burden of oesophageal cancer
and its attributable risk factors in 195 countries and territories,
1990–2017: A systematic analysis for the Global Burden of Disease
Study 2017. Lancet Gastroenterol Hepatol. 5:582–597. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Medical Affairs Bureau of the National
Health and Health Commission of the People's Republic of China, .
Esophageal cancer diagnosis and treatment guidelines (2022
edition). Zhonghua Wei Chang Wai Ke Za Zhi. 21:1247–1268. 2022.(In
Chinese).
|
|
3
|
Sasaki Y and Kato K: Chemoradiotherapy for
esophageal squamous cell cancer. Jpn J Clin Oncol. 46:805–810.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Watanabe M, Otake R, Kozuki R, Toihata T,
Takahashi K, Okamura A and Imamura Y: Recent progress in
multidisciplinary treatment for patients with esophageal cancer.
Surg Today. 50:12–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun JM, Shen L, Shah MA, Enzinger P,
Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al:
Pembrolizumab plus chemotherapy versus chemotherapy alone for
first-line treatment of advanced oesophageal cancer (KEYNOTE-590):
A randomised, placebo-controlled, phase 3 study. Lancet.
398:759–771. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L,
Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, et al: Nivolumab
combination therapy in advanced esophageal squamous-cell carcinoma.
N Engl J Med. 386:449–462. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song Y, Zhang B, Xin D, Kou X, Tan Z,
Zhang S, Sun M, Zhou J, Fan M, Zhang M, et al: First-line
serplulimab or placebo plus chemotherapy in PD-L1-positive
esophageal squamous cell carcinoma: A randomized, double-blind
phase 3 trial. Nat Med. 29:473–482. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu J, Kato K, Raymond E, Hubner RA, Shu Y,
Pan Y, Park SR, Ping L, Jiang Y, Zhang J, et al: Tislelizumab plus
chemotherapy versus placebo plus chemotherapy as first-line
treatment for advanced or metastatic oesophageal squamous cell
carcinoma (RATIONALE-306): A global, randomised,
placebo-controlled, phase 3 study. Lancet Oncol. 24:483–495. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q,
Zhang Y, Zhao K, Chen Z, Gao S, et al: Effect of camrelizumab vs
placebo added to chemotherapy on survival and progression-free
survival in patients with advanced or metastatic esophageal
squamous cell carcinoma: The ESCORT-1st Randomized clinical trial.
JAMA. 326:916–925. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoy SM: Sintilimab: First global approval.
Drugs. 79:341–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu Y, Liao L, Du K, Mo J, Zou X, Liang J,
Chen J, Tang W, Su L, Wu J, et al: Clinical activity and safety of
sintilimab, bevacizumab, and TMZ in patients with recurrent
glioblastoma. BMC Cancer. 24:1332024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li F, Zhang DB, Ma Y, Song Y and Duan XL:
Effects of combined sintilimab and chemotherapy on progression-free
survival and overall survival in osteosarcoma patients with
metastasis. Pak J Med Sci. 40:648–651. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou SQ, Wan P, Zhang S, Ren Y, Li HT and
Ke QH: Programmed cell death 1 inhibitor sintilimab plus concurrent
chemoradiotherapy for locally advanced pancreatic adenocarcinoma.
World J Clin Oncol. 15:859–866. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang
L, Wang B, Sun G, Ji Y, Cao G, et al: Sintilimab versus placebo in
combination with chemotherapy as first line treatment for locally
advanced or metastatic oesophageal squamous cell carcinoma
(ORIENT-15): Multicentre, randomised, double blind, phase 3 trial.
BMJ. 377:e0687142022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohm JE, Gabrilovich DI, Sempowski GD,
Kisseleva E, Parman KS, Nadaf S and Carbone DP: VEGF inhibits
T-cell development and may contribute to tumor-induced immune
suppression. Blood. 101:4878–4886. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu H, Chen Y, Tan S, Wu S, Huang Y, Fu S,
Luo F and He J: The research Progress of antiangiogenic therapy,
immune therapy and tumor microenvironment. Front Immunol.
13:8028462022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun Y, Wang JW, Liu YY, Yu QT, Zhang YP,
Li K, Xu LY, Luo SX, Qin FZ, Chen ZT, et al: Long-term results of a
randomized, double-blind, and placebo-controlled phase III trial:
Endostar (rhendostatin) versus placebo in combination with
vinorelbine and cisplatin in advanced non-small cell lung cancer.
Thorac Cancer. 4:440–448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pu X, Wang Q, Liu L, Chen B, Li K, Zhou Y,
Sheng Z, Liu P, Tang Y, Xu L, et al: Rh-endostatin plus
camrelizumab and chemotherapy in first-line treatment of advanced
non-small cell lung cancer: A multicenter retrospective study.
Cancer Med. 12:7724–7733. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang H, Zhong P, Zhu X, Fu S, Li S, Peng
S, Liu Y, Lu Z and Chen L: Immunotherapy combined with
rh-endostatin improved clinical outcomes over immunotherapy plus
chemotherapy for second-line treatment of advanced NSCLC. Front
Oncol. 13:11372242023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Yao Q, Huang M, Wang B, Zhang J,
Wang T, Ming Y, Zhou X, Jia Q, Huan Y, et al: A randomized Phase
III trial of neoadjuvant recombinant human endostatin, docetaxel
and epirubicin as first-line therapy for patients with breast
cancer (CBCRT01). Int J Cancer. 142:2130–2138. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Jin F, Jiang S, Cao J, Meng Y, Xu
Y, ChunmengWan g, Chen Y, Yang H, Kong Y, et al: Rh-endostatin
combined with chemotherapy in patients with advanced or recurrent
mucosal melanoma: retrospective analysis of real-world data. Invest
New Drugs. 40:453–460. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsuchida Y and Therasse P: Response
evaluation criteria in solid tumors (RECIST): New guidelines. Med
Pediatr Oncol. 37:1–3. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chinese Anti-Cancer Association, . Chinese
expert consensus on PD-L1 immunohistochemical detection criteria
for non-small cell lung cancer. Chin J Lung Cancer. 23:733–740.
2020.
|
|
24
|
Mischel AM and Rosielle DA: Eastern
Cooperative Oncology Group Performance Status #434. J Palliat Med.
25:508–510. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
National Cancer Institute, . Common
Terminology Criteria for Adverse Events v3.0 (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfFebruary
6–2024
|
|
26
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bureau of Medical Administration and
National Health Commission of the People's Republic of China, .
Standardization for diagnosis and treatment of esophageal cancer
(2022 edition). Chin J Dig Surg. 21:1247–1268. 2022.(In
Chinese).
|
|
28
|
Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z,
Liu S, Meng L, Xin Y and Jiang X: Targeting hypoxia in the tumor
microenvironment: A potential strategy to improve cancer
immunotherapy. J Exp Clin Cancer Res. 40:242021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khan KA and Kerbel RS: Improving
immunotherapy outcomes with anti-angiogenic treatments and vice
versa. Nat Rev Clin Oncol. 15:310–324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baas P, Scherpereel A, Nowak AK, Fujimoto
N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et
al: First-line nivolumab plus ipilimumab in unresectable malignant
pleural mesothelioma (CheckMate 743): A multicentre, randomised,
open-label, phase 3 trial. Lancet. 397:375–386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fukumura D, Kloepper J, Amoozgar Z, Duda
DG and Jain RK: Enhancing cancer immunotherapy using
antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol.
15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tian L, Goldstein A, Wang H, Ching Lo H,
Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, et
al: Mutual regulation of tumour vessel normalization and
immunostimulatory reprogramming. Nature. 544:250–254. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schmidt EV: Developing combination
strategies using PD-1 checkpoint inhibitors to treat cancer. Semin
Immunopathol. 41:21–30. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Voron T, Colussi O, Marcheteau E, Pernot
S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N,
Tanchot C, et al: VEGF-A modulates expression of inhibitory
checkpoints on CD8(+) T cells in tumors. J Exp Med. 212:139–148.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Allen E, Jabouille A, Rivera LB,
Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D,
Michael IP and Bergers G: Combined antiangiogenic and anti-PD-L1
therapy stimulates tumor immunity through HEV formation. Sci Transl
Med. 9:eaak96792017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Manning EA, Ullman JG, Leatherman JM,
Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM and
Emens LA: A vascular endothelial growth factor receptor-2 inhibitor
enhances antitumor immunity through an immune-based mechanism. Clin
Cancer Res. 13:3951–3959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fuming Qiu, Fan J, Shao M, Yao J, Zhao L,
Zhu L, Li B, Fu Y, Li L, Yang Y, et al: Efficacy of two - and
three-cycle neoadjuvant sinadilizumab plus platinum-based
double-agent chemotherapy in patients with resectable non-small
cell lung cancer (neoSCORE): A randomized, single-center, two-arm
Phase II trial. J Clin Oncol. 40:8500. 2022. View Article : Google Scholar
|
|
38
|
Huizing MT, Keung AC, Rosing H, van der
Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM
and Beijnen JH: Pharmacokinetics of paclitaxel and metabolites in a
randomized comparative study in platinum-pretreated ovarian cancer
patients. J Clin Oncol. 11:2127–2135. 1993. View Article : Google Scholar : PubMed/NCBI
|
